ClearNote Health advanced its commercialization plans for pancreatic cancer screening by presenting new performance data for its Avantect Pancreatic Cancer test after adding a glycan biomarker to its epigenetic foundation. In a validation cohort of 1,445 high-risk patients (259 with cancer), overall sensitivity reached 82.6% with specificity reported at 97.5%. The assay combines quantitative 5-hydroxymethylcytosine (5hmC) measurements in cell-free DNA with cfDNA fragment size genotyping, then adjusts results using FUT2/3 genotyping to create a tumor-specific glycan signature that incorporates CA19-9. ClearNote also reported that performance in sub-cohorts—including patients with new-onset type 2 diabetes—remained broadly consistent, supporting the approach as a potentially scalable multi-signal screening platform.